Medical and Hospital News
INTERN DAILY
Google AI health chatbot passes US medical exam: study
Google AI health chatbot passes US medical exam: study
by AFP Staff Writers
Paris (AFP) July 12, 2023

Google's artificial intelligence-powered medical chatbot has achieved a passing grade on a tough US medical licensing exam, but it's answers still fall short of those from human doctors, a peer-reviewed study said on Wednesday.

Last year the release of ChatGPT -- whose developer OpenAI is backed by Google's rival Microsoft -- kicked off a race between tech giants in the burgeoning field of AI.

While much has been made about the future possibilities -- and dangers -- of AI, health is one area where the technology had already shown tangible progress, with algorithms able to read certain medical scans as well as humans.

Google first unveiled its AI tool for answering medical questions, called Med-PaLM, in a preprint study in December. Unlike ChatGPT, it has not been released to the public.

The US tech giant says Med-PaLM is the first large language model, an AI technique trained on vast amounts of human-produced text, to pass the US Medical Licensing Examination (USMLE).

A passing grade for the exam, which is taken by medical students and physicians-in-training in the United States, is around 60 percent.

In February, a study said that ChatGPT had achieved passing or near passing results.

In a peer-reviewed study published in the journal Nature on Wednesday, Google researchers said that Med-PaLM had achieved 67.6 percent on USMLE-style multiple choice questions.

"Med-PaLM performs encouragingly, but remains inferior to clinicians," the study said.

To identify and cut down on "hallucinations" -- the name for when AI models offer up false information -- Google said it had developed a new evaluation benchmark.

Karan Singhal, a Google researcher and lead author of the new study, told AFP that the team has used the benchmark to test a newer version of their model with "super exciting" results.

Med-PaLM 2 has reached 86.5 percent on the USMLE exam, topping the previous version by nearly 20 percent, according to a preprint study released in May that has not been peer-reviewed.

- 'Elephant in the room' -

James Davenport, a computer scientist at the UK's University of Bath not involved in the research, said "there is an elephant in the room" for these AI-powered medical chatbots.

There is a big difference between answering "medical questions and actual medicine," which includes diagnosing and treating genuine health problems," he said.

Anthony Cohn, an AI expert at the UK's Leeds University, said that hallucinations would likely always be a problem for such large language models, because of their statistical nature.

Therefore these models "should always be regarded as assistants rather than the final decision makers," Cohn said.

Singhal said that in the future Med-PaLM could be used to support doctors to offer up alternatives that may not have been considered otherwise.

The Wall Street Journal reported earlier this week that Med-PaLM 2 has been in testing at the prestigious US Mayo Clinic research hospital since April.

Singhal said he could not speak about specific partnerships.

But he emphasised that any testing would not be "clinical, or patient facing, or are able to cause patients harm".

It would instead be for "more administrative tasks that can be relatively easily automated, with low stakes," he added.

Related Links
Hospital and Medical News at InternDaily.com

Subscribe Free To Our Daily Newsletters
Tweet

RELATED CONTENT
The following news reports may link to other Space Media Network websites.
INTERN DAILY
First drug developed by generative AI administered to patients
Washington DC (UPI) Jul 2, 2023
The first dose of a drug developed by artificial intelligence has been delivered to its first patient. Insilico Medicine, a biotechnology company based in Hong Kong, announced that human patients have begun receiving the drug INS018_055, an anti-fibrotic small molecule inhibitor. The company said the drug was discovered and designed with generative AI. The drug has passed through two phases of trials before being administered to human patients. "With demonstrated potential against ... read more

INTERN DAILY
New Zealand confident in UN advice on Fukushima, govt says

IAEA chief meets top S. Korean diplomat amid protest

South Korea co-signs Japan's Fukushima radioactive water release plan

Drills, red wine: Ukrainians ready for leak at Russia-held plant

INTERN DAILY
Northrop Grumman's new airborne navigation system achieves successful flight test

Fugro and GomSpace deliver world class position and timing accuracy onboard LEO satellites

GMV to head up Galileo ground segment after securing a new contract

LEO PNT satellite signal simulator debuts at JNC 2023 conference

INTERN DAILY
The sound of silence? Researchers prove people hear it

The Anthropocene heralds disaster. Can humans change course?

Signs of the human era, from nuclear fallout to microplastics

Welcome to the Anthropocene, Earth's new chapter

INTERN DAILY
Global study finds while humans sheltered in place, wildlife roamed

South Korea welcomes birth of first giant panda twins

EU parliament backs biodiversity bill in close vote

Key EU biodiversity bill may be scrapped as elections draw near

INTERN DAILY
MIT researchers to lead a new center for continuous mRNA manufacturing

Moderna signs agreement towards making mRNA medicine in China

No evidence Covid created in Chinese lab: US intelligence

Brimful clinics, cemeteries as dengue ravages Peru

INTERN DAILY
Hong Kong prosecutors gain new powers in national security trials

China's Xi says army must 'dare to fight' during military inspection

Hong Kong: a turbulent road since the handover

Yellen hopes to visit China to 'reestablish contact' with leaders

INTERN DAILY
US sanctions Chinese, Mexican entities over drug equipment

Malaysia searches Chinese ship suspected of looting WWII wrecks

INTERN DAILY
Subscribe Free To Our Daily Newsletters




The content herein, unless otherwise known to be public domain, are Copyright 1995-2024 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. All articles labeled "by Staff Writers" include reports supplied to Space Media Network by industry news wires, PR agencies, corporate press officers and the like. Such articles are individually curated and edited by Space Media Network staff on the basis of the report's information value to our industry and professional readership. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. General Data Protection Regulation (GDPR) Statement Our advertisers use various cookies and the like to deliver the best ad banner available at one time. All network advertising suppliers have GDPR policies (Legitimate Interest) that conform with EU regulations for data collection. By using our websites you consent to cookie based advertising. If you do not agree with this then you must stop using the websites from May 25, 2018. Privacy Statement. Additional information can be found here at About Us.